Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy | Zendy

Shivshankari Rajkumar | Zendy; Diana Berry | Zendy; Kayla A. Heney | Zendy; Colton Strong | Zendy; LeeAnn Ramsay | Zendy; Mathieu Lajoie | Zendy; Rached Alkallas | Zendy; Tan-Trieu Nguyen | Zendy; Cameron G. Thomson | Zendy; Mozhdeh Ahanfeshar-Adams | Zendy; Matthew Dankner | Zendy; Teresa M. Petrella | Zendy; April A. N. Rose | Zendy; Peter M. Siegel | Zendy; Ian R. Watson | Zendy

Open Access

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy

Author(s) -

Shivshankari Rajkumar,

Diana Berry,

Kayla A. Heney,

Colton Strong,

LeeAnn Ramsay,

Mathieu Lajoie,

Rached Alkallas,

Tan-Trieu Nguyen,

Cameron G. Thomson,

Mozhdeh Ahanfeshar-Adams,

Matthew Dankner,

Teresa M. Petrella,

April A. N. Rose,

Peter M. Siegel,

Ian R. Watson

Publication year - 2022

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2022.110634

Subject(s) - neuroblastoma ras viral oncogene homolog , melanoma , mutant , cancer research , mek inhibitor , mutation , combination therapy , trametinib , context (archaeology) , in vivo , targeted therapy , medicine , mapk/erk pathway , biology , kinase , cancer , kras , pharmacology , genetics , gene , paleontology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research